Company profile for ONL Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal disease and conditions.​Based on its industry-leading expertise in retinal neuroprotection, ONL is developing breakthrough, first-in-class treatments for serious, vision-threatening retinal diseases and conditions. Preclinical in vivo data, along with a growing body of lite...
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal disease and conditions.​Based on its industry-leading expertise in retinal neuroprotection, ONL is developing breakthrough, first-in-class treatments for serious, vision-threatening retinal diseases and conditions. Preclinical in vivo data, along with a growing body of literature, support application of the company’s technology platform in retinal detachment, age-related macular degeneration (AMD), glaucoma and non-infectious uveitis, among other chronic retinal diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
PO Box 131547 Ann Arbor, MI 48113
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/10/3184356/0/en/ONL-Therapeutics-to-Present-at-EYENOVATE-and-the-FLORetina-ICOOR-Congress-2025.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/10/28/3175222/0/en/ONL-Therapeutics-Announces-Randomization-of-First-Patient-in-Global-Phase-2-GALAXY-Trial-of-Xelafaslatide-ONL1204-in-Patients-with-Geographic-Atrophy-GA-Associated-with-Dry-AMD.html

GLOBENEWSWIRE
28 Oct 2025

https://www.globenewswire.com/news-release/2025/02/04/3020123/0/en/ONL-Therapeutics-Announces-Multiple-Presentations-at-Leading-Ophthalmology-Meetings.html

GLOBENEWSWIRE
04 Feb 2025

https://www.globenewswire.com/news-release/2025/01/07/3005245/0/en/ONL-Therapeutics-Appoints-Penny-Fleck-as-Chief-Development-Officer.html

GLOBENEWSWIRE
07 Jan 2025

https://www.globenewswire.com/news-release/2024/09/13/2945851/0/en/ONL-Therapeutics-Closes-65-Million-in-Oversubscribed-Series-D-Financing.html

GLOBENEWSWIRE
13 Sep 2024

https://www.globenewswire.com/news-release/2024/09/10/2943524/0/en/ONL-Therapeutics-to-Present-at-the-57th-Annual-Scientific-Meeting-of-The-Retina-Society-and-EURETINA-Innovation-Spotlight.html

GLOBENEWSWIRE
10 Sep 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty